- Published at
- by manilatimes.net
positive
positive
News for Precision BioSciences, Inc. (DTIL)
- Published at
- by seekingalpha.com
positivepositivePrecision Bio stock gains on Hep B drug data (DTIL:NASDAQ)
Precision BioSciences (NASDAQ:DTIL) stock gains as company reports promising Phase 1 trial results for its Hepatitis B gene therapy, PBGENE-HBV. Read more here.- Published at
- by gurufocus.com
positivepositiveAquilo Capital Management, LLC Increases Stake in Precision BioSciences Inc
On December 31, 2024, Aquilo Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 410,059 shares of Precision BioScien- Published at
- by gurufocus.com
positivepositiveLynx1 Capital Management LP Acquires Significant Stake in Precision BioSciences Inc
Overview of the Recent Transaction On December 31, 2024, Lynx1 Capital Management LP (Trades, Portfolio) executed a notable transaction by acquiring 766,051 sha- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
mixedmixedMaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERTâ„¢ platform to support the development and commercialization of azer-cel, its all- Published at
- by investing.com
positivepositivePrecision Biosciences CEO sells $172,033 in stock By Investing.com
Precision Biosciences CEO sells $172,033 in stock- Published at
- by seekingalpha.com
negativenegativePrecision Bio stock rises after trial data (DTIL:NASDAQ)
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating OTC deficiency. Read more here.- Published at
- by benzinga.com
mixedmixedWhy Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Aviat Networks (NASDAQ:AVNW), Bridger Aerospace Gr (NASDAQ:BAER)
Shares of Zoomcar Holdings Inc ZCAR rose sharply in today's pre-market trading after the company announced a significant achievement in its financial performanc...- Published at
- by gurufocus.com
mixedmixedPrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edit- Published at
- by gurufocus.com
positivepositiveInsider Buying: Geno Germano Acquires Shares in Precision BioSciences Inc (DTIL)
On December 30, 2024, Geno Germano, Director at Precision BioSciences Inc (DTIL), purchased 3,605 shares of the company. Following this transaction, the insider- Published at
- by investing.com
positivepositivePrecision BioSciences stock hits 52-week low at $4.12 By Investing.com
Precision BioSciences stock hits 52-week low at $4.12- Published at
- by investing.com
positivepositivePrecision Biosciences CFO buys $10,036 in common stock By Investing.com
Precision Biosciences CFO buys $10,036 in common stock- Published at
- by investing.com
positivepositivePrecision BioSciences stock hits 52-week low at $6.4 By Investing.com
Precision BioSciences stock hits 52-week low at $6.4- Published at
- by investing.com
neutralneutralPrecision BioSciences stock hits 52-week low at $7.94 By Investing.com
Precision BioSciences stock hits 52-week low at $7.94- Published at
- by investing.com
positivepositivePrecision BioSciences begins clinical trial for hepatitis B cure By Investing.com
Precision BioSciences begins clinical trial for hepatitis B cure- Published at
- by globenewswire.com
mixedmixedAllogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
The allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in...- Published at
- by investing.com
positivepositivePrecision BioSciences files for gene editing trial By Investing.com
Precision BioSciences files for gene editing trial- Published at
- by financialpost.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedGenome Editing Market to Surpass Market Valuation of USD 31.15 Billion by 2031 | SkyQuest Technology
Global Genome Editing Market size was valued at USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast...